| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Boon Chuan Low | Q50619779 |
| P2093 | author name string | Yu Zong Chen | |
| Zhe Shi | |||
| Yuyang Jiang | |||
| Chunyan Tan | |||
| Mei Lin Go | |||
| Xiao Hua Ma | |||
| P2860 | cites work | Mechanisms of drug combinations: interaction and network perspectives | Q83265745 |
| The influence of target family and functional activity on the physicochemical properties of pre-clinical compounds | Q83314137 | ||
| Targeting multiple kinases in glioblastoma multiforme | Q83395665 | ||
| IQGAP1 modulates activation of B-Raf | Q24309982 | ||
| IQGAP proteins are integral components of cytoskeletal regulation | Q24535739 | ||
| Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3 | Q24633878 | ||
| Identifying regulatory networks by combinatorial analysis of promoter elements | Q28215713 | ||
| Prospect of a dopamine contribution in the next generation of antidepressant drugs: the triple reuptake inhibitors | Q28256136 | ||
| Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial | Q28268831 | ||
| In-vitro and in-vivo characterization of JNJ-7925476, a novel triple monoamine uptake inhibitor | Q28281128 | ||
| Sunitinib versus interferon alfa in metastatic renal-cell carcinoma | Q28282757 | ||
| Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application | Q28300751 | ||
| HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells | Q28473274 | ||
| Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies | Q29615606 | ||
| Recent advances in the development of multi-kinase inhibitors | Q30319311 | ||
| Novel paradigms for drug discovery: computational multitarget screening | Q30662767 | ||
| Virtual screening of chemical libraries | Q33209939 | ||
| A support vector machines approach for virtual screening of active compounds of single and multiple mechanisms from large libraries at an improved hit-rate and enrichment factor | Q33316422 | ||
| Development and experimental validation of a docking strategy for the generation of kinase-targeted libraries | Q33334594 | ||
| Discovery of novel small-molecule inhibitors of human epidermal growth factor receptor-2: combined ligand and target-based approach. | Q33337443 | ||
| Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia | Q33387517 | ||
| IQGAP1-dependent signaling pathway regulates endothelial cell proliferation and angiogenesis | Q33388951 | ||
| Kinase-targeted library design through the application of the PharmPrint methodology | Q33389288 | ||
| Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching | Q33393829 | ||
| Virtual screening of Abl inhibitors from large compound libraries by support vector machines | Q33494643 | ||
| Current combination chemotherapy regimens for metastatic breast cancer | Q33516194 | ||
| A phase II study of flavopiridol (Alvocidib) in combination with docetaxel in refractory, metastatic pancreatic cancer | Q33739625 | ||
| Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials | Q33832656 | ||
| Pyrroloisoquinoline antidepressants. 2. In-depth exploration of structure-activity relationships | Q34163535 | ||
| Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy | Q34294256 | ||
| Multicomponent therapeutics for networked systems | Q34390417 | ||
| Structure of the aspartic protease plasmepsin 4 from the malarial parasite Plasmodium malariae bound to an allophenylnorstatine-based inhibitor | Q34498794 | ||
| New pharmacological developments in the treatment of hepatocellular cancer | Q43234592 | ||
| Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies | Q43282879 | ||
| COMT-inhibition increases serum levels of dihydroxyphenylacetic acid (DOPAC) in patients with advanced Parkinson's disease | Q43856051 | ||
| Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia | Q43899710 | ||
| Phase II study of flavopiridol in patients with advanced colorectal cancer | Q44525933 | ||
| Collaborative filtering on a family of biological targets. | Q45966036 | ||
| Classifying "kinase inhibitor-likeness" by using machine-learning methods. | Q45966554 | ||
| In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models | Q46173286 | ||
| Co-expression of receptor tyrosine kinases in esophageal adenocarcinoma and squamous cell cancer | Q46349962 | ||
| Evaluation of virtual screening performance of support vector machines trained by sparsely distributed active compounds. | Q46366065 | ||
| Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL--Inhibition of P-glycoprotein function by 17-AAG. | Q46497571 | ||
| CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia | Q46610628 | ||
| Maximum common binding modes (MCBM): consensus docking scoring using multiple ligand information and interaction fingerprints | Q46797503 | ||
| 5-HT reuptake inhibitors with 5-HT(1B/1D) antagonistic activity: a new approach toward efficient antidepressants | Q46892497 | ||
| Flt-1-Dependent Survival Characterizes the Epithelial-Mesenchymal Transition of Colonic Organoids | Q47592144 | ||
| Alignment-free prediction of a drug-target complex network based on parameters of drug connectivity and protein sequence of receptors. | Q51772250 | ||
| Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks. | Q51858888 | ||
| "Bayes affinity fingerprints" improve retrieval rates in virtual screening and define orthogonal bioactivity space: when are multitarget drugs a feasible concept? | Q51928206 | ||
| Multi-target spectral moments for QSAR and Complex Networks study of antibacterial drugs. | Q51929655 | ||
| Unify QSAR approach to antimicrobials. Part 1: predicting antifungal activity against different species. | Q51940356 | ||
| Analysis of activity space by fragment fingerprints, 2D descriptors, and multitarget dependent transformation of 2D descriptors. | Q51941405 | ||
| Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. | Q53348981 | ||
| Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. | Q53545899 | ||
| Predicting the Predictability: A Unified Approach to the Applicability Domain Problem of QSAR Models | Q61999169 | ||
| The physicochemical challenges of designing multiple ligands | Q80048530 | ||
| Unified QSAR and network-based computational chemistry approach to antimicrobials, part 1: multispecies activity models for antifungals | Q81592130 | ||
| Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors | Q34519442 | ||
| Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases | Q34531564 | ||
| Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity | Q34580980 | ||
| Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer | Q34613941 | ||
| Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines | Q34735192 | ||
| ZD-6474. AstraZeneca. | Q35648815 | ||
| ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia | Q35751114 | ||
| Crosstalk of oncogenic and prostanoid signaling pathways | Q35810119 | ||
| Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics | Q35848830 | ||
| Regulation of monoamine transporters: influence of psychostimulants and therapeutic antidepressants | Q36341704 | ||
| Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer | Q36472437 | ||
| The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. | Q36765297 | ||
| Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition | Q36800953 | ||
| A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development | Q36907537 | ||
| Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells | Q37003553 | ||
| Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia | Q37059746 | ||
| Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma | Q37071204 | ||
| Turning promiscuous kinase inhibitors into safer drugs | Q37134826 | ||
| Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a review of recent clinical trials | Q37161261 | ||
| Early clinical studies of novel therapies for thyroid cancers | Q37172796 | ||
| Imatinib treatment for gastrointestinal stromal tumour (GIST). | Q37334993 | ||
| Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy | Q37336035 | ||
| Activity of the multikinase inhibitor dasatinib against ovarian cancer cells | Q37424063 | ||
| Comparative analysis of machine learning methods in ligand-based virtual screening of large compound libraries | Q37481572 | ||
| Synergistic therapeutic actions of herbal ingredients and their mechanisms from molecular interaction and network perspectives | Q37512729 | ||
| Flavopiridol in chronic lymphocytic leukemia: a concise review | Q37602859 | ||
| Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion | Q38431410 | ||
| Characteristics of dasatinib- and imatinib-resistant chronic myelogenous leukemia cells | Q39933573 | ||
| Pharmacophore modelling and virtual screening for identification of new Aurora-A kinase inhibitors | Q39992285 | ||
| The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells | Q40105425 | ||
| Combined treatment of bladder cancer cell lines with lapatinib and varying chemotherapy regimens--evidence of schedule-dependent synergy | Q40167169 | ||
| Roscovitine inhibits differentiation and invasion in a three-dimensional skin reconstruction model of metastatic melanoma | Q40168436 | ||
| The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases | Q40365711 | ||
| CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. | Q40480723 | ||
| Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970. | Q40526681 | ||
| Monoamine oxidase and catecholamine metabolism | Q40635509 | ||
| A combination of cisplatin-eluting gelatin microspheres and flavopiridol enhances anti-tumour effects in a rabbit VX2 liver tumour model | Q41993498 | ||
| Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol | Q42545705 | ||
| P433 | issue | 5 | |
| P921 | main subject | in silico | Q192572 |
| drug discovery | Q1418791 | ||
| drug screening | Q10505555 | ||
| P304 | page(s) | 739-749 | |
| P577 | publication date | 2010-03-11 | |
| P1433 | published in | Pharmaceutical Research | Q7180737 |
| P1476 | title | In-silico approaches to multi-target drug discovery : computer aided multi-target drug design, multi-target virtual screening | |
| P478 | volume | 27 |
| Q103831973 | A Multi-Objective Approach for Anti-Osteosarcoma Cancer Agents Discovery through Drug Repurposing |
| Q50114279 | A desirability-based multi objective approach for the virtual screening discovery of broad-spectrum anti-gastric cancer agents. |
| Q27902271 | A ranking method for the concurrent learning of compounds with various activity profiles |
| Q38206286 | Advances in quantitative structure-activity relationship models of anti-Alzheimer's agents. |
| Q28486030 | An innovative strategy for dual inhibitor design and its application in dual inhibition of human thymidylate synthase and dihydrofolate reductase enzymes |
| Q36009999 | Bioinformatics and variability in drug response: a protein structural perspective |
| Q30426852 | Cardiac models in drug discovery and development: a review |
| Q28476812 | Cardio-protection of salvianolic acid B through inhibition of apoptosis network |
| Q38232706 | Chemo- and bioinformatics resources for in silico drug discovery from medicinal plants beyond their traditional use: a critical review |
| Q57161239 | Computational Modeling of Electrophysiology and Pharmacotherapy of Atrial Fibrillation: Recent Advances and Future Challenges |
| Q36687860 | Computational analysis and predictive modeling of polymorph descriptors |
| Q38907478 | Computational approaches for innovative antiepileptic drug discovery |
| Q47242194 | Computer-aided design of multi-target ligands at A1R, A2AR and PDE10A, key proteins in neurodegenerative diseases |
| Q33894409 | DRAR-CPI: a server for identifying drug repositioning potential and adverse drug reactions via the chemical-protein interactome |
| Q33566835 | Designing of dual inhibitors for GSK-3β and CDK5: Virtual screening and in vitro biological activities study |
| Q28477930 | Drug discovery using chemical systems biology: weak inhibition of multiple kinases may contribute to the anti-cancer effect of nelfinavir |
| Q41863562 | Inferring multi-target QSAR models with taxonomy-based multi-task learning. |
| Q62495870 | Machine Learning-based Virtual Screening and Its Applications to Alzheimer's Drug Discovery: A Review |
| Q36097620 | Multi-target pharmacology: possibilities and limitations of the "skeleton key approach" from a medicinal chemist perspective |
| Q34530512 | Multiple virtual screening approaches for finding new hepatitis C virus RNA-dependent RNA polymerase inhibitors: structure-based screens and molecular dynamics for the pursue of new poly pharmacological inhibitors |
| Q42249570 | Novel phytochemical-antibiotic conjugates as multitarget inhibitors of Pseudomononas aeruginosa GyrB/ParE and DHFR. |
| Q93202753 | Prospects of multitarget drug designing strategies by linking molecular docking and molecular dynamics to explore the protein-ligand recognition process |
| Q64904165 | Rapid Investigation and Screening of Bioactive Components in Simo Decoction via LC-Q-TOF-MS and UF-HPLC-MD Methods. |
| Q51738057 | System-level multi-target drug discovery from natural products with applications to cardiovascular diseases. |
| Q89509291 | The Roles of the NLRP3 Inflammasome in Neurodegenerative and Metabolic Diseases and in Relevant Advanced Therapeutic Interventions |
| Q37880903 | The Therapeutic Target Database: an internet resource for the primary targets of approved, clinical trial and experimental drugs |
| Q28538871 | The use of functional chemical-protein associations to identify multi-pathway renoprotectants |
| Q35631111 | Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. |
| Q38901429 | Toward the development of dual-targeted glyceraldehyde-3-phosphate dehydrogenase/trypanothione reductase inhibitors against Trypanosoma brucei and Trypanosoma cruzi. |
| Q38712793 | Use of machine learning approaches for novel drug discovery |
| Q28478631 | Using multiple microenvironments to find similar ligand-binding sites: application to kinase inhibitor binding |
Search more.